Surrozen, Inc.

SRZN Nasdaq SEC CIK 1824893
Follow Surrozen Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $0 −100% vs same quarter last year
Net income −$129.7M −81.1% vs same quarter last year
EPS, diluted −$11.02 −31.8% vs same quarter last year
Operating cash flow −$4.8M +46.6% vs same quarter last year
Revenue by quarter
$655K
$983K
$983K
$983K
$528K
$5M
$5M
$0
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
  • Revenue
  • Net income
−$300M−$200M−$100M$0$100MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$3.5M−$242M
FY24$10.7M−$63.6M
FY23$0−$43M
FY22$12.5M−$36M
FY21$0−$54.6M
FY20-−$32.7M
FY19--
MarginsShare of revenue
  • Operating margin
  • Net margin
−8000%−6000%−4000%−2000%0%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−1210.6%−6960.8%
FY24−239.7%−596.6%
FY23--
FY22−354.7%−288%
FY21--
FY20--
FY19--
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$30.4M
FY24−$17.7M
FY23−$40.8M
FY22−$44.9M
FY21−$50.1M
FY20−$30M
FY19-
Returned to shareholdersDividends paid and shares bought back
$0$1M$2M$3MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearBuybacks
FY25-
FY24-
FY23$0
FY22$2.6M
FY21$0
FY20-
FY19-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Surrozen
  • Healthcare median
−8000%−6000%−4000%−2000%0%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearSurrozenHealthcare median
FY25−6960.8%−30.6%
FY24−596.6%−47%
FY23-−58%
FY22−288%−80.4%
FY21-−71.9%
FY20-−62.2%
FY19-−46.3%